Safety of Programmed Death–1 Pathway Inhibitors Among Patients With Non–Small-Cell Lung Cancer and Preexisting Autoimmune DisordersGiulia C. Leonardi, Mark M. Awad, Justin F. Gainor et al.|Journal of Clinical Oncology|2018Cited by 356
Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysisMark M. Awad, Rebecca S. Heist, D. Ross Camidge et al.|Lung Cancer|2019Cited by 113
Impact of MET inhibitors on survival among patients (pts) with <i>MET</i> exon 14 mutant (<i>MET</i>del14) non-small cell lung cancer (NSCLC).Mark M. Awad, Rebecca S. Heist, Giulia C. Leonardi et al.|Journal of Clinical Oncology|2017Cited by 32